FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 309:630-636 September 15, 1983 Number 11 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We identified 18 patients with an inversion of chromosome 16, inv(16)(p13q22), among 308 patients with newly diagnosed acute nonlymphocytic leukemia. Each of these 18 patients had acute myelomonocytic leukemia (M4 subtype) and eosinophils with distinctly abnormal morphology, cytochemical staining, and ultrastructure. These eosinophils constituted from 1 to 33 per cent of the nucleated marrow cells. In our series, every patient with acute myelomonocytic leukemia and abnormal eosinophils also had an abnormal chromosome 16. This subgroup of M4 patients had a good response to intensive therapy designed to induce remission; 13 of 17 treated patients entered a complete remission, and 10 remain in first remission. Thus, patients with an inversion of chromosome 16 appear to represent a unique cytogenetic-clinicopathological subtype of acute nonlymphocytic leukemia with a favorable prognosis.

This article has been cited by other articles:

• Pulsoni, A., Iacobelli, S., Bernardi, M., Borgia, M., Camera, A., Cantore, N., Di Raimondo, F., Fazi, P., Ferrara, F., Leoni, F., Liso, V., Mancini, M., Marmont, F., Matturro, A., Maurillo, L., Melillo, L., Meloni, G., Mirto, S., Specchia, G., Valentini, C. G., Venditti, A., Leone, G., Foa, R., Mandelli, F., Pagano, L. (2008). M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience. haematol 93: 1025-1032 [Abstract] [Full Text]  
• Streetman, D. S. (2007). Clinical Pharmacogenetics of the Major Adenosine Triphosphate Binding Cassette and Solute Carrier Drug Transporters. Journal of Pharmacy Practice 20: 219-233 [Abstract]  
• Cairoli, R., Beghini, A., Grillo, G., Nadali, G., Elice, F., Ripamonti, C. B., Colapietro, P., Nichelatti, M., Pezzetti, L., Lunghi, M., Cuneo, A., Viola, A., Ferrara, F., Lazzarino, M., Rodeghiero, F., Pizzolo, G., Larizza, L., Morra, E. (2006). Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 107: 3463-3468 [Abstract] [Full Text]  
• Schlenk, R.F., Benner, A., Krauter, J., Buchner, T., Sauerland, C., Ehninger, G., Schaich, M., Mohr, B., Niederwieser, D., Krahl, R., Pasold, R., Dohner, K., Ganser, A., Dohner, H., Heil, G. (2004). Individual Patient Data-Based Meta-Analysis of Patients Aged 16 to 60 Years With Core Binding Factor Acute Myeloid Leukemia: A Survey of the German Acute Myeloid Leukemia Intergroup. JCO 22: 3741-3750 [Abstract] [Full Text]  
• Merchant, S. H., Haines, S., Hall, B., Hozier, J., Viswanatha, D. S. (2004). Fluorescence In Situ Hybridization Identifies Cryptic t(16;16)(p13;q22) Masked By del(16)(q22) in a Case of AML-M4 Eo. J. Mol. Diagn. 6: 271-274 [Abstract] [Full Text]  
• Gotlib, J., Cools, J., Malone, J. M. III, Schrier, S. L., Gilliland, D. G., Coutre, S. E. (2004). The FIP1L1-PDGFR{alpha} fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 103: 2879-2891 [Abstract] [Full Text]  
• Huang, G., Shigesada, K., Wee, H.-J., Liu, P. P., Osato, M., Ito, Y. (2004). Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera. Blood 103: 3200-3207 [Abstract] [Full Text]  
• Byrd, J. C., Ruppert, A. S., Mrozek, K., Carroll, A. J., Edwards, C. G., Arthur, D. C., Pettenati, M. J., Stamberg, J., Koduru, P. R.K., Moore, J. O., Mayer, R. J., Davey, F. R., Larson, R. A., Bloomfield, C. D. (2004). Repetitive Cycles of High-Dose Cytarabine Benefit Patients With Acute Myeloid Leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461. JCO 22: 1087-1094 [Abstract] [Full Text]  
• Delaunay, J., Vey, N., Leblanc, T., Fenaux, P., Rigal-Huguet, F., Witz, F., Lamy, T., Auvrignon, A., Blaise, D., Pigneux, A., Mugneret, F., Bastard, C., Dastugue, N., Van den Akker, J., Fiere, D., Reiffers, J., Castaigne, S., Leverger, G., Harousseau, J.-L., Dombret, H. (2003). Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood 102: 462-469 [Abstract] [Full Text]  
• Haferlach, T., Schoch, C., Loffler, H., Gassmann, W., Kern, W., Schnittger, S., Fonatsch, C., Ludwig, W.-D., Wuchter, C., Schlegelberger, B., Staib, P., Reichle, A., Kubica, U., Eimermacher, H., Balleisen, L., Gruneisen, A., Haase, D., Aul, C., Karow, J., Lengfelder, E., Wormann, B., Heinecke, A., Sauerland, M. C., Buchner, T., Hiddemann, W. (2003). Morphologic Dysplasia in De Novo Acute Myeloid Leukemia (AML) Is Related to Unfavorable Cytogenetics but Has No Independent Prognostic Relevance Under the Conditions of Intensive Induction Therapy: Results of a Multiparameter Analysis From the German AML Cooperative Group Studies. JCO 21: 256-265 [Abstract] [Full Text]  
• Buonamici, S., Ottaviani, E., Testoni, N., Montefusco, V., Visani, G., Bonifazi, F., Amabile, M., Terragna, C., Ruggeri, D., Piccaluga, P. P., Isidori, A., Malagola, M., Baccarani, M., Tura, S., Martinelli, G. (2002). Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood 99: 443-449 [Abstract] [Full Text]  
• McKenna, R. W. (2000). Multifaceted Approach to the Diagnosis and Classification of Acute Leukemias. Clin. Chem. 46: 1252-1259 [Abstract] [Full Text]  
• van der Kolk, D. M., Vellenga, E., van der Veen, A. Y., Noordhoek, L., Timmer-Bosscha, H., Ossenkoppele, G. J., Raymakers, R. A., Muller, M., van den Berg, E., de Vries, E. G. E. (2000). Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity. Blood 95: 3514-3519 [Abstract] [Full Text]  
• Lowenberg, B., Downing, J. R., Burnett, A. (1999). Acute Myeloid Leukemia. NEJM 341: 1051-1062 [Full Text]  
• Adya, N., Stacy, T., Speck, N. A., Liu, P. P. (1998). The Leukemic Protein Core Binding Factor beta  (CBFbeta )-Smooth-Muscle Myosin Heavy Chain Sequesters CBFalpha 2 into Cytoskeletal Filaments and Aggregates. Mol. Cell. Biol. 18: 7432-7443 [Abstract] [Full Text]  
• Britos-Bray, M., Ramirez, M., Cao, W., Wang, X., Liu, P. P., Civin, C. I., Friedman, A. D. (1998). CBFbeta -SMMHC, Expressed in M4eo Acute Myeloid Leukemia, Reduces p53 Induction and Slows Apoptosis in Hematopoietic Cells Exposed to DNA-Damaging Agents. Blood 92: 4344-4352 [Abstract] [Full Text]  
• Kogan, S. C., Lagasse, E., Atwater, S., Bae, S.-c., Weissman, I., Ito, Y., Bishop, J. M. (1998). The PEBP2beta MYH11 fusion created by Inv(16)(p13;q22) in myeloid leukemia impairs neutrophil maturation and contributes to granulocytic dysplasia. Proc. Natl. Acad. Sci. USA 95: 11863-11868 [Abstract] [Full Text]  
• Viswanatha, D. S., Chen, I.-M., Liu, P. P., Slovak, M. L., Rankin, C., Head, D. R., Willman, C. L. (1998). Characterization and Use of an Antibody Detecting the CBFbeta -SMMHC Fusion Protein in inv(16)/t(16;16)-Associated Acute Myeloid Leukemias. Blood 91: 1882-1890 [Abstract] [Full Text]  
• Liu, P, Tarle, S., Hajra, A, Claxton, D., Marlton, P, Freedman, M, Siciliano, M., Collins, F. (1993). Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science 261: 1041-1044 [Abstract]  
• Simmers, R., Sutherland, G., West, A, Richards, R. (1987). Fragile sites at 16q22 are not at the breakpoint of the chromosomal rearrangement in AMMoL. Science 236: 92-94 [Abstract]